TGTX — TG Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $3.25bn
- $3.14bn
- $233.66m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.152 | 0.152 | 6.69 | 2.79 | 234 |
Cost of Revenue | |||||
Gross Profit | — | — | 5.9 | 2.52 | 220 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 169 | 274 | 351 | 196 | 213 |
Operating Profit | -169 | -274 | -345 | -193 | 20.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -173 | -279 | -348 | -198 | 13.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -173 | -279 | -348 | -198 | 12.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -173 | -279 | -348 | -198 | 12.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -173 | -279 | -348 | -198 | 12.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.96 | -2.42 | -2.63 | -1.46 | 0.085 |